Clinical trial Recruiting at 1 site Observational Ages 18 and up Women only

Developing organoids from breast cancer tissue

Official title: Developing Breast (Cancer) Organoids

Run by Maastricht Radiation Oncology · NCT05317221 · Data updated 2026-11-12

This study is trying to create mini versions of breast cancer tumors from patient samples to see how they can help doctors understand the disease better and choose the best treatments for each person.

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment60 (estimated)
SponsorMaastricht Radiation Oncology
Academic / other
Locations1 site (Maastricht)
StatusRecruiting
StartedSeptember 1, 2022
Main results expectedApril 1, 2028
Study endsMay 1, 2028
Registry record updatedMay 12, 2026
Trial IDNCT05317221 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are female patients over 18 years old with a confirmed diagnosis of breast cancer who are undergoing primary surgery.

Probably not a fit

Patients who are physically or mentally incapable of providing informed consent will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a living biobank of breast cancer organoids derived from patient tissue samples collected during routine surgical procedures. By obtaining small samples of excised tumors and blood for genetic analysis, the study seeks to understand how these organoids reflect disease progression, treatment response, and relapse across different breast cancer subtypes. The goal is to develop a patient-tailored clinical model that addresses tumor heterogeneity and guides individualized treatment selection without altering the standard care process for participants.

Why it matters

Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for breast cancer patients.

How similar studies have gone: Other studies have shown promise in using organoids for drug response screening, indicating potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female,
* \>18 years,
* Family Anamneses
* Breast cancer (proven by histopathology), Included subtypes; (ER-,PR- HER2-); (ER+, PR+, HER2-); (ER+, PR+ HER2+).
* Primary surgery (lumpectomy or mastectomy)

Exclusion Criteria:

\- Physically or mentally incapable or incompetent to sign informed consent

Where it's running

  • Maastricht University Medical Center
    Maastricht, Netherlands
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.